Generic Pharmaceuticals Contract Manufacturing Market Report 2026

The generic pharmaceuticals contract manufacturing market size has grown strongly in recent years. It will grow from $66.82 billion in 2025 to $71.65 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to limited contract manufacturing options, reliance on in-house generic drug production, rising demand for off-patent apis, increasing generic drug approvals, cost pressures on pharmaceutical companies.

The generic pharmaceuticals contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $93.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growth in global generic drug demand, expansion of contract manufacturing organizations (cmos), adoption of advanced formulation technologies, rising focus on biologics and complex generics, increased cross-border regulatory collaborations. Major trends in the forecast period include rising outsourcing of generic drug manufacturing, focus on cost-efficient production and packaging, expansion of injectable and tablet manufacturing services, increased regulatory support and compliance services, growth in licensing and technology transfer for generic products.

The growing demand for biosimilars is anticipated to drive the expansion of the generic pharmaceuticals contract manufacturing market in the coming years. Biosimilars are biological medical products that closely resemble approved reference biologics, with no clinically meaningful differences in safety, purity, or effectiveness. The increasing adoption of biosimilars is mainly driven by their ability to offer more affordable alternatives to high-cost biologic therapies, thereby improving access to advanced treatments for patients and healthcare systems. Generic pharmaceuticals contract manufacturing plays a key role in supporting biosimilars by offering cost-efficient, large-scale manufacturing capabilities along with regulatory expertise required to speed up market entry and maintain consistent product quality. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, there were 33 FDA-approved biosimilar products in the US, with 21 available on the market, and by 2023, the number of FDA-approved biosimilars had increased to 40, of which 25 were commercially available. As a result, the rising demand for biosimilars is contributing to the growth of the generic pharmaceuticals contract manufacturing market.

Key companies operating in the generic pharmaceutical contract manufacturing market are broadening their service offerings by creating dedicated subsidiaries to address the increasing demand for outsourced development and manufacturing services. This approach of establishing specialized subsidiaries allows organizations to optimize the production of active pharmaceutical ingredients (APIs), while ensuring regulatory compliance, scalability, and operational efficiency throughout the drug development lifecycle. For instance, in July 2025, Lupin, an India-based generic pharmaceutical company, launched a new subsidiary, Lupin Manufacturing Solutions (LMS), to expand into the contract development and manufacturing organization (CDMO) space. This specialized unit is focused on supporting the development, manufacturing, and commercialization of APIs for global pharmaceutical partners. Backed by a leadership team with extensive experience in biotechnology and pharmaceuticals, the subsidiary is well positioned to deliver high-quality contract manufacturing services, enabling pharmaceutical companies to shorten time-to-market while maintaining regulatory compliance and cost efficiency.

In April 2024, Bora Pharmaceuticals, a Taiwan-based contract development and manufacturing organization (CDMO), acquired Upsher-Smith Laboratories for $210 million. This acquisition added manufacturing capacity and technical expertise, strengthening Bora’s capabilities across the pharmaceutical value chain, including drug development, manufacturing, quality assurance, packaging, and distribution. Upsher-Smith Laboratories is a US-based company that specializes in providing generic pharmaceutical contract manufacturing services.

Major companies operating in the generic pharmaceuticals contract manufacturing market are WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Curia Global Inc., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Alcami Corp. Inc, Neuland Laboratories Limited.

North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generic pharmaceuticals contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the generic pharmaceuticals contract manufacturing market by increasing costs of imported active pharmaceutical ingredients, packaging materials, and formulation equipment. Segments such as bulk API manufacturing, injectable production, and cost-efficient packaging are particularly affected, with Asia-Pacific regions like India and China facing significant import duties. While tariffs create cost challenges and supply chain adjustments, they also encourage local sourcing, domestic manufacturing investments, and innovation in production processes, potentially strengthening regional manufacturing capabilities.

The generic pharmaceuticals contract manufacturing market research report is one of a series of new reports that provides generic pharmaceuticals contract manufacturing market statistics, including generic pharmaceuticals contract manufacturing industry global market size, regional shares, competitors with a generic pharmaceuticals contract manufacturing market share, detailed generic pharmaceuticals contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the generic pharmaceuticals contract manufacturing industry. This generic pharmaceuticals contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generic pharmaceuticals contract manufacturing involves the outsourcing of generic drug production activities to third-party manufacturers. These service providers offer capabilities such as formulation development, active pharmaceutical ingredient manufacturing, tablet or injectable production, packaging, and regulatory assistance, enabling pharmaceutical companies to lower operational costs and concentrate on their core business functions.

The primary drug categories in generic pharmaceuticals contract manufacturing include branded generics and unbranded generics. Branded generics are off-patent medicines that are sold under a proprietary brand name by a pharmaceutical company, despite containing the same active ingredients as the original branded drug. The various product types comprise pharmaceutical active pharmaceutical ingredients, formulations, capsules, tablets, and injectables. These products are delivered through multiple routes of administration, including oral, parenteral, topical, and others. They are utilized across a wide range of therapeutic applications, such as oncology, immunology, antidiabetics, neurology, anticoagulants, cardiovascular, respiratory, pain management, and human immunodeficiency virus antivirals, and serve diverse end-user industries including pharmaceutical companies, contract research organizations, biotechnology companies, and generic drug manufacturers.

The generic pharmaceuticals contract manufacturing market consists of sales of creams, syrups, sterile formulations, topical medications, and high-potency generic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.